Clinical-stage biotech company developing AAV gene therapies for rare and retinal diseases.
About
REGENXBIO is a clinical-stage biotechnology company focused on developing gene therapies using its proprietary NAV Technology Platform, which utilizes adeno-associated virus (AAV) vectors. The company aims to improve lives by delivering one-time treatments for rare and retinal diseases, as well as metabolic and neurodegenerative conditions. Their pipeline includes investigational therapies for Duchenne muscular dystrophy, MPS II, MPS I, and wet age-related macular degeneration.
Tags
Total Employees
396
Current headcount
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Regenxbio do?
REGENXBIO is a clinical-stage biotechnology company focused on developing gene therapies using its proprietary NAV Technology Platform, which utilizes adeno-associated virus (AAV) vectors. The company aims to improve lives by delivering one-time treatments for rare and retinal diseases, as well as metabolic and neurodegenerative conditions. Their pipeline includes investigational therapies for Duchenne muscular dystrophy, MPS II, MPS I, and wet age-related macular degeneration.
How much funding has Regenxbio raised?
Regenxbio has raised a total of $180M in funding. The most recent round on record is Funding Round.
Where is Regenxbio headquartered?
Regenxbio is headquartered in Rockville, United States.
When was Regenxbio founded?
Regenxbio was founded in 2008.
What industry does Regenxbio operate in?
Regenxbio operates in Biotech, MedTech, HealthTech, Drug Discovery, Clinical Trials, Gene Therapy.
How many employees does Regenxbio have?
Regenxbio has approximately 396 people on record.